The use of statins in combination with lifestyle interventions has emerged as a promising strategy for preventing cardiovascular disease among people living with HIV, with moderate-intensity statins now recommended for all people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease (ASCVD). While these updated guidelines serve as a starting point for the management of cardiovascular risk in this population, individuals with HIV could benefit from refined risk calculators and therapeutic targets that are tailored to their specific needs.
In providing preventative care to this population, health care providers must navigate a complex clinical landscape shaped by diverse cardiovascular risk profiles, therapeutic interactions, and adherence challenges.
Source : TheBodyPro
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.